Science ImmunologyImmunologyPeer-reviewed journal article
Autoantigen TRIM21 (Ro52) assembles pro-inflammatory immune complexes following lytic cell death
Esther L. Jones EvansiD, Benjamin DemarcoiD, Han CaiiD, Madelon M.E. de JongiD, Sarah HilliD, Marcus A. WiddessiD, Joannah R. FergussoniD, Ryan E. GlassiD, Gemma HarrisiD, G MeadiD, Yavuz F. YaziciogluiD, Saba NayariD, Benjamin A. FisheriD, Mark Steven CraggiD, Alexander J. ClarkeiD, Audrey GérardiD, Jelena S. BezbradicaiD, Lynn B. DustiniD
Abstract
Sjogrens disease (SjD) causes localised and systemic inflammation due to autoantibody production against intracellular proteins, such as TRIM21/Ro52. TRIM21 is an E3 ubiquitin ligase which binds antibody Fc domains on opsonised pathogens, which have escaped extracellular immunity and entered cytosols; TRIM21 ubiquitinates these, driving their proteasomal degradation. How and why TRIM21 becomes an autoantigen remains unclear. We show that TRIM21 is released upon lytic cell death (pyroptosis/necroptosis) but not apoptosis. Released TRIM21 binds circulating antibody Fc domains, and forms large immune complexes (ICs). These are further enhanced with TRIM21/Ro52 seropositive SjD plasma antibodies, where interactions are mediated via both Fc and F(ab)2 domains. TRIM21-ICs are taken up by macrophages, which in high interferon environments drive pro-inflammatory responses, antigen presentation, and inflammatory and metabolic transcriptional changes. Whilst many cytosolic proteins are released by dead cells, due to its high affinity for antibodies, TRIM21 can generate large ICs. This may perpetuate inflammation and antigen presentation, causing TRIM21 to be highly autoimmunogenic. One Sentence SummaryHow the intracellular protein TRIM21 becomes an autoantigen.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 4
- FWCI
- 15.32
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Apoptotic bodies from patients with Sjogren's disease drive atypical memory B cell and macrophage activation and autoantibody production
Adrian Y. S. Lee, Bo Shi, … Joanne H. Reed·bioRxiv·Jul 20, 2026
- Lupus IgA1 autoantibodies synergize with IgG to enhance plasmacytoid dendritic cell responses to RNA-containing immune complexes
H. R. Waterman, M. J. Dufort, … J. A. Hamerman·bioRxiv·Sep 7, 2023
- Loss of TRIM21 drives UVB-induced systemic inflammation by regulating DNA-sensing pathways
Gantsetseg Tumurkhuu, Graziela Perri, … Caroline Anne Jefferies·Arthritis & RheumatologyPeer-reviewed·Jun 17, 2025
- Context-dependent miR-21 regulation of TLR7-mediated autoimmune and foreign antigen driven antibody-forming cell and germinal center responses
S. Schell, K. N. Bricker, … Z. S. M. Rahman·bioRxiv·Mar 12, 2021
- SCARF1-induced efferocytosis plays an immunomodulatory role in humans, and autoantibodies targeting SCARF1 are produced in patients with systemic lupus erythematosus
A. M. Jorge, T. Lao, … Z. G. Ramirez-Ortiz·bioRxiv·May 24, 2021
- Lupus Immune Complexes Drive Distinct Pro-Inflammatory Monocyte and Macrophage Populations Independent of Type I Interferon
Lais Osmani, Min Sun Shin, … Insoo Kang·bioRxiv·Apr 24, 2026